ALERTS: CARTELS - HORIZONTAL AGREEMENT - RESTRICTION BY OBJECT - LICENSE AGREEMENT - PHARMACEUTICAL LABORATORIES - OFF-LABEL THERAPEUTIC USE

Off-label therapeutic use: The European Court of Justice rules that constitutes a restriction of competition by object the cartel between two pharmaceutical laboratories selling two competitors medicines, consisting in diffusing to the European Medicines Agency, health professionals and the general public, in a context of scientific uncertainty, misleading informations on the undesirable effects of the off-label use of one of those medicine (Hoffman-La Roche)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 23 January 2018, the Court of Justice of the European Union delivered its judgment in case C-179/16 (F. Hoffmann-La Roche Ltd and others v Autorità Garante della Concorrenza e del Mercato (AGCM)). The present case, which stems from a reference for a preliminary ruling by the Italian Conseil d'État, concerns concerted action by undertakings - in this case pharmaceutical undertakings - seeking to put an end to or at least to limit a practice of prescribing and marketing a medicinal product with a view to 'off-label' uses, that is to say, the use of a medicinal product outside the therapeutic indications and via a method of administration not covered by the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Off-label therapeutic use: The European Court of Justice rules that constitutes a restriction of competition by object the cartel between two pharmaceutical laboratories selling two competitors medicines, consisting in diffusing to the European Medicines Agency, health professionals and the general public, in a context of scientific uncertainty, misleading informations on the undesirable effects of the off-label use of one of those medicine (Hoffman-La Roche), 23 January 2018, Concurrences N° 2-2018, Art. N° 86047, www.concurrences.com

Visites 512

All reviews